Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

2001
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 1
2004 1
2006 2
2007 2
2008 3
2009 2
2010 1
2011 2
2012 4
2014 2
2015 4
2016 3
2017 1
2018 4
2019 1
2020 4
2021 5
2022 1
2023 5
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.
Bramante CT, Buse JB, Liebovitz DM, Nicklas JM, Puskarich MA, Cohen K, Belani HK, Anderson BJ, Huling JD, Tignanelli CJ, Thompson JL, Pullen M, Wirtz EL, Siegel LK, Proper JL, Odde DJ, Klatt NR, Sherwood NE, Lindberg SM, Karger AB, Beckman KB, Erickson SM, Fenno SL, Hartman KM, Rose MR, Mehta T, Patel B, Griffiths G, Bhat NS, Murray TA, Boulware DR; COVID-OUT Study Team. Bramante CT, et al. Lancet Infect Dis. 2023 Oct;23(10):1119-1129. doi: 10.1016/S1473-3099(23)00299-2. Epub 2023 Jun 8. Lancet Infect Dis. 2023. PMID: 37302406 Free PMC article. Clinical Trial.
The metformin beneficial effect was consistent across prespecified subgroups. When metformin was started within 3 days of symptom onset, the HR was 0.37 (95% CI 0.15-0.95). There was no effect on cumulative incidence of long COVID with ivermectin (HR 0.99, 95% CI 0.59-1.64 …
The metformin beneficial effect was consistent across prespecified subgroups. When metformin was started within 3 days of symptom ons …
Antiretroviral Therapy for the Prevention of HIV-1 Transmission.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Cottle L, Zhang XC, Makhema J, Mills LA, Panchia R, Faesen S, Eron J, Gallant J, Havlir D, Swindells S, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano DD, Essex M, Hudelson SE, Redd AD, Fleming TR; HPTN 052 Study Team. Cohen MS, et al. N Engl J Med. 2016 Sep 1;375(9):830-9. doi: 10.1056/NEJMoa1600693. Epub 2016 Jul 18. N Engl J Med. 2016. PMID: 27424812 Free PMC article. Clinical Trial.
In the early-ART group, 886 participants started therapy at enrollment (CD4+ count, 350 to 550 cells per cubic millimeter). In the delayed-ART group, 877 participants started therapy after two consecutive CD4+ counts fell below 250 cells per cubic millimeter or if a …
In the early-ART group, 886 participants started therapy at enrollment (CD4+ count, 350 to 550 cells per cubic millimeter). In the de …
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lockman S, Brummel SS, Ziemba L, Stranix-Chibanda L, McCarthy K, Coletti A, Jean-Philippe P, Johnston B, Krotje C, Fairlie L, Hoffman RM, Sax PE, Moyo S, Chakhtoura N, Stringer JS, Masheto G, Korutaro V, Cassim H, Mmbaga BT, João E, Hanley S, Purdue L, Holmes LB, Momper JD, Shapiro RL, Thoofer NK, Rooney JF, Frenkel LM, Amico KR, Chinula L, Currier J; IMPAACT 2010/VESTED Study Team and Investigators. Lockman S, et al. Lancet. 2021 Apr 3;397(10281):1276-1292. doi: 10.1016/S0140-6736(21)00314-7. Lancet. 2021. PMID: 33812487 Free PMC article. Clinical Trial.
In this trial we compared the safety and efficacy of three antiretroviral regimens started in pregnancy: dolutegravir, emtricitabine, and tenofovir alafenamide fumarate; dolutegravir, emtricitabine, and tenofovir disoproxil fumarate; and efavirenz, emtricitabine, and tenof …
In this trial we compared the safety and efficacy of three antiretroviral regimens started in pregnancy: dolutegravir, emtricitabine, …
Fetomaternal alloimmune thrombocytopenia.
Ahya R, Turner ML, Urbaniak SJ; SNAIT Study Team. Ahya R, et al. Transfus Apher Sci. 2001 Oct;25(2):139-45. doi: 10.1016/s1473-0502(01)00102-1. Transfus Apher Sci. 2001. PMID: 11761276 Review.
The Scottish National Blood Transfusion Service started a study in August 1999 on 25,000 pregnancies to carry out a cost benefit analysis of routine antenatal screening. ...
The Scottish National Blood Transfusion Service started a study in August 1999 on 25,000 pregnancies to carry out a cost benefit anal …
Virological and immunological features of SARS-COV-2 infected children with distinct symptomatology.
Cotugno N, Ruggiero A, Pascucci GR, Bonfante F, Petrara MR, Pighi C, Cifaldi L, Zangari P, Bernardi S, Cursi L, Santilli V, Manno EC, Amodio D, Linardos G, Piccioni L, Barbieri MA, Perrotta D, Campana A, Donà D, Giaquinto C; CACTUS Study Team; Concato C, Brodin P, Rossi P, De Rossi A, Palma P. Cotugno N, et al. Pediatr Allergy Immunol. 2021 Nov;32(8):1833-1842. doi: 10.1111/pai.13585. Epub 2021 Jul 16. Pediatr Allergy Immunol. 2021. PMID: 34174102 Free PMC article.
BACKGROUND: Although SARS-CoV-2 immunizations have started in most countries, children are not currently included in the vaccination programs; thus, it remains crucial to define their anti-SARS-CoV-2 immune response in order to minimize the risk for other epidemic waves. . …
BACKGROUND: Although SARS-CoV-2 immunizations have started in most countries, children are not currently included in the vaccination …
HLA-B*5701 screening for hypersensitivity to abacavir.
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A; PREDICT-1 Study Team. Mallal S, et al. N Engl J Med. 2008 Feb 7;358(6):568-79. doi: 10.1056/NEJMoa0706135. N Engl J Med. 2008. PMID: 18256392 Free article. Clinical Trial.
We randomly assigned patients to undergo prospective HLA-B*5701 screening, with exclusion of HLA-B*5701-positive patients from abacavir treatment (prospective-screening group), or to undergo a standard-of-care approach of abacavir use without prospective HLA-B*5701 screening (con …
We randomly assigned patients to undergo prospective HLA-B*5701 screening, with exclusion of HLA-B*5701-positive patients from abacavir trea …
Estradiol and Spironolactone Plasma Pharmacokinetics Among Brazilian Transgender Women Using HIV Pre-Exposure Prophylaxis: Analysis of Potential Interactions.
Cattani VB, Jalil EM, Eksterman L, Torres T, Wagner Cardoso S, Castro CRV, Monteiro L, Wilson E, Bushman L, Anderson P, Veloso VG, Grinsztejn B, Estrela R; PrEParadas study team. Cattani VB, et al. Clin Pharmacokinet. 2023 Jul;62(7):1031-1041. doi: 10.1007/s40262-023-01248-0. Epub 2023 Jun 1. Clin Pharmacokinet. 2023. PMID: 37261664 Free PMC article. Clinical Trial.
Participants had a first PK assessment (PK1) 15 days after FHT (estradiol valerate 2-6 mg plus spironolactone 100-200 mg) initiation and then started PrEP (tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg). A second PK evaluation was performed 12 weeks later (PK2) …
Participants had a first PK assessment (PK1) 15 days after FHT (estradiol valerate 2-6 mg plus spironolactone 100-200 mg) initiation and the …
Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) Trial.
Masheto G, Brummel SS, Ziemba L, Shepherd J, Mbengeranwa T, Igawa L, Coletti A, Mukura D, Rossouw L, Theron G, Krotje C, Jean-Philippe P, Chakhtoura N, Cassim H, Mathiba SR, Maena J, Murtaugh W, Fairlie L, Currier J, Hoffman R, Chinula L, Sax PE, Stranix-Chibanda L, Lockman S; IMPAACT 2010/VESTED Study Team and Investigators. Masheto G, et al. J Acquir Immune Defic Syndr. 2024 Oct 1;97(2):172-179. doi: 10.1097/QAI.0000000000003478. J Acquir Immune Defic Syndr. 2024. PMID: 39250651 Clinical Trial.
We evaluated maternal bone and renal data from the International Maternal Pediatric Adolescent AIDS Clinical Trials Network 2010 trial, which compared the safety and efficacy of 3 antiretroviral therapy regimens started in pregnancy: dolutegravir + emtricitabine/tenofovir …
We evaluated maternal bone and renal data from the International Maternal Pediatric Adolescent AIDS Clinical Trials Network 2010 trial, whic …
Risk Factors Associated With SARS-CoV-2 Infection Among Farmworkers in Monterey County, California.
Mora AM, Lewnard JA, Kogut K, Rauch SA, Hernandez S, Wong MP, Huen K, Chang C, Jewell NP, Holland N, Harris E, Cuevas M, Eskenazi B; CHAMACOS-Project-19 Study Team. Mora AM, et al. JAMA Netw Open. 2021 Sep 1;4(9):e2124116. doi: 10.1001/jamanetworkopen.2021.24116. JAMA Netw Open. 2021. PMID: 34524438 Free PMC article.
Individuals were eligible if they were not pregnant, were 18 years or older, had conducted farmwork since the pandemic started, and were proficient in English or Spanish. Survey data were collected and SARS-CoV-2 tests were conducted among participants from July 16 to Nove …
Individuals were eligible if they were not pregnant, were 18 years or older, had conducted farmwork since the pandemic started, and w …
Acute retroviral syndrome is associated with lower CD4 + T cell nadir and delayed viral suppression, which are blunted by immediate antiretroviral therapy initiation.
Gabert R, Lama JR, Valdez R, Dasgupta S, Cabello R, Sanchez H, Leon M, Huamani JV, MacRae J, Montalban E, Pasalar S, Ignacio RB, Duerr A; (for the Sabes Study team). Gabert R, et al. AIDS. 2023 Jun 1;37(7):1103-1108. doi: 10.1097/QAD.0000000000003511. Epub 2023 Mar 14. AIDS. 2023. PMID: 36779502 Free PMC article. Clinical Trial.
Immediate ART blunted effects on symptoms, CD4 + cell count and viral load, as associations were strongest in the arm that started ART after 24 weeks. Detrimental associations of ARS with CD4 + counts, and CD4 + /CD8 + ratio were not maintained at 2 or 4 years. ...
Immediate ART blunted effects on symptoms, CD4 + cell count and viral load, as associations were strongest in the arm that started AR …
51 results